Preventing CMV after kidney transplant: comparing two drug plans
Part of Immune system & allergy, Infections, Kidney & urinary clinical trials.
This trial tests two different medication strategies to prevent cytomegalovirus (CMV) infection after a kidney transplant. It compares a plan that uses tacrolimus plus an mTOR inhibitor and only treats if CMV appears, versus a standard plan of tacrolimus plus mycophenolic acid with universal prevention therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You tested positive for CMV IgG before your transplant (meaning you've been exposed to CMV in the past).
- You received a specific type of anti-rejection induction therapy called thymoglobulin (between 1 and 5 doses).
- You are willing to sign a consent form agreeing to join the study.
- You are not infected with HIV.
- You did not receive a different induction therapy called basiliximab, and you are not expected to need complex vascular surgery or have polycystic kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This trial tests a special machine that washes a donated kidney with a drug to remove a common virus called CMV before transplant. It may help prevent the virus from infecting the person who receives the kidney.
This trial tests whether adding a specific immunosuppressive drug called everolimus can help treat cytomegalovirus (CMV)—a common viral infection that occurs after organ transplants. If you've had an organ transplant and developed a CMV infection, this study may help your medical team find better ways to manage it.
Hear when a new Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.